Hematology & Oncology
Division of Hematology and Oncology
 |
Long H. Dang, MD, PhD Associate Professor Division of Hematology / Oncology University of Florida 1600 SW Archer Road/Box 100277 Gainesville, FL 32610-0277 (352) 273-7832/FAX (352) 273-5006 |
Long H. Dang, MD PhD is a board certified medical oncologist with expertise in GI oncology. He is an Associate Professor in the Division of Hematology & Oncology and co-Director of the Oncology Phase I Program.
Training:
| Degree Program |
Institution | Field/Specialty |
| BA (magna cum laude) | Harvard University | Biochemistry |
| MD PhD | Harvard Medical School | Medicine/Immunology |
| Residency | University of Pennsylvania | Internal Medicine |
| Fellowship | Johns Hopkins Hospital | Medical Oncology |
Research Interests:
Dr. L. Dang’s research interests are in the translational and clinical development of combination therapy targeting the tumor vasculature and cancer cell survival mechanisms in the tumor microenvironment. Using gene knockout models, he has found that targeted disruption of both the VEGF pathway and the hypoxia-inducible transcription factors (HIF-1 and HIF-2) survival pathway to be synergistic. He has also found novel HIF targets which may be tested as predictive biomarkers and as targets for therapy. To translate these concepts, he is working with the drug discovery team to develop novel compounds using both high throughput and in silico drug screens.
Clinical Interests:
Diagnosis and treatment of GI cancer and Phase I drug development
Representative Publications:
- Dang DT, Chen F, Kohli M, Rago C, Cummins J, and Dang LH (2005) Glutathione S-transferase pi 1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Research, 65(20):9485-9494.
- Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV, Dang LH (2006) HIF-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Research, 66(3):1684-96.
- Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ (2007) 1α,25-dihydroxyvitamin D3 (Calcitriol) reduces VEGF via the HIF pathway in human cancer cells. Molecular Cancer Therapeutics, 6(4):1433-9.
- Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Blayney DW, Ensminger WD, St. Croix B, Dang NH, Dang LH (2008) HIF-1 target genes as indicators of tumor vessel response to VEGF inhibition. Cancer Research, 68(6):1872-80.
- Burkitt K, Chun SY, Dang DT, Dang LH (2009) Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Molecular Cancer Therapeutics, 8(5):1148-56.